Ardelyx announces first patient dosed in ACCEL

Ardely announced that the first patient has been dosed in ACCEL, a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA for the treatment of chronic idiopathic constipation, CIC, in adults. “Today marks an important milestone for our team and the patients we are committed to serving,” said Laura Williams, M.D., M.P.H, chief patient officer and interim chief medical officer of Ardelyx (ARDX). “We are pleased to announce that the first patient has been dosed in the ACCEL Phase 3 clinical trial, an integral step to bringing IBSRELA and its differentiated mechanism of action to patients with chronic idiopathic constipation. This achievement reflects the dedication of our investigators, clinical staff, internal team, and most importantly, the patients and families who entrust us with their care. We remain focused on conducting this study with the highest standards of safety, integrity and scientific rigor, and we look forward to the insights it will provide for the future health of our patients.”